<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3654">
  <stage>Registered</stage>
  <submitdate>21/09/2012</submitdate>
  <approvaldate>21/09/2012</approvaldate>
  <nctid>NCT01699529</nctid>
  <trial_identification>
    <studytitle>Multi-electrode Radiofrequency Renal Denervation System Feasibility Study</studytitle>
    <scientifictitle>Multi-electrode Radiofrequency Renal Denervation System Feasibility Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>10058715DOC</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Uncontrolled Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system

Experimental: Renal Denervation - 


Treatment: devices: Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system
The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute safety as measured by procedural complications</outcome>
      <timepoint>1 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Office Systolic Blood Pressure</outcome>
      <timepoint>Baseline to 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Individual is = 18 and = 80 years old.

          -  Individual has an office systolic blood pressure of 160 mmHG or greater (= 150 mmHg
             for Type 2 diabetics) based on an average of 3 office/clinic blood pressure readings

          -  Individual is adhering to a stable medication regimen including = 3 anti-hypertensive
             medications(preferred that one is a diuretic) for a minimum of two weeks prior to
             screening.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Individual has an estimated glomerular filtration rate (eGFR) of &lt; 45 mL/min/1.73 m2

          -  Individual has type 1 diabetes mellitus

          -  Individual requires chronic oxygen support or mechanical ventilation (e.g.,
             tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea.

          -  Individual has primary pulmonary hypertension.

          -  Individual is pregnant, nursing or planning to be pregnant.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <hospital>St. Vincent's Hospital Melbourne - Melbourne</hospital>
    <hospital>Epworth Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3065 - Melbourne</postcode>
    <postcode>3069 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, single-arm, non-randomized and open label feasibility study. The study
      is intended to evaluate safety and efficacy of multi-electrode radiofrequency renal
      denervation in patients with uncontrolled hypertension.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01699529</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert Whitbourn, MD</name>
      <address>St Vincent's Hospital Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>